Improved survival times in multiple myeloma treated with melphalan, prednisone, cyclophosphamide, vincristine and BCNU: M-2 protocol
- 1 December 1977
- journal article
- research article
- Published by Elsevier BV in American Journal Of Medicine
- Vol. 63 (6), 897-903
- https://doi.org/10.1016/0002-9343(77)90543-5
Abstract
No abstract availableThis publication has 21 references indexed in Scilit:
- DOXORUBICIN/B.C.N.U. CHEMOTHERAPY FOR MULTIPLE MYELOMA IN RELAPSEThe Lancet, 1976
- Cellular Kinetics in Multiple MyelomaArchives of Internal Medicine, 1975
- Remission Maintenance Therapy for Multiple MyelomaArchives of Internal Medicine, 1975
- Expansion of the growth fraction in multiple myeloma with alkylating agentsBlood, 1975
- Combination chemotherapy of multiple myeloma with Alkeran, Cytoxan, vincristine, prednisone, and BCNUCancer, 1974
- Plasma cell myeloma. An interpretive reviewCancer, 1972
- Combination chemotherapy for multiple myelomaCancer, 1972
- Treatment for Multiple MyelomaJAMA, 1969
- Clinical trials with N-isopropyl-α-(2-methylhydrazino)-p-toluamide hydrochloride in malignant lymphoma and other disseminated neoplasiaCancer, 1967
- Multiple MyelomaPublished by American Medical Association (AMA) ,1964